Inquiry Basket
Loading ......
The human immune system is a formidable network of cells, tissues, and molecules designed to defend the body against foreign invaders. A key feature of this system is the production of antibodies—specialized proteins that recognize and neutralize specific targets known as antigens. However, the immune response is not always beneficial. In some cases, the body may develop antibodies against therapeutic agents, a phenomenon that can undermine treatment efficacy and lead to adverse reactions. Furthermore, monitoring the presence and concentration of free drug targets, such as the protein CD79b, is essential for understanding disease progression and therapeutic outcomes.
Many of today's most advanced therapies are biological molecules, such as monoclonal antibodies, that are designed to intervene in specific disease pathways. For instance, Polatuzumab vedotin is an antibody-drug conjugate that targets the CD79b protein, a component of the B-cell receptor complex, making it a valuable tool in treating certain B-cell malignancies. When a patient receives a therapeutic antibody like Polatuzumab, the goal is for the drug to bind to its target and exert a beneficial effect. However, from the perspective of the immune system, this administered antibody may appear as a foreign substance. Consequently, the patient's immune system can mount a response by generating anti-drug antibodies (ADAs) . ADAs can bind to the therapeutic antibody, forming immune complexes that may:
The detection and quantification of these anti-drug antibodies are therefore not just a matter of academic curiosity but a crucial component of patient management and clinical trial monitoring. A negative result for ADAs suggests that the drug is likely not being targeted by the patient's immune system, allowing it to function as intended.
CD79b, also known as B29 or Ig beta, is an integral protein forming part of the B-cell receptor complex alongside surface immunoglobulin. This receptor is vital for B-cell development, differentiation, and activation. In pathological contexts, CD79b is expressed on the surface of normal B-cells as well as a majority of malignant B-cells, making it an ideal therapeutic target. The pathology of many B-cell lymphomas and leukemias is driven by dysregulated B-cell signaling. Aberrant activation of the B-cell receptor pathway, in which CD79b plays a central role, can promote the survival and proliferation of malignant cells. By targeting CD79b, antibody-drug conjugates can deliver a cytotoxic payload selectively to tumor cells, while minimizing damage to healthy tissues. The measurement of free Anti-CD79b or its related biomarkers is essential for evaluating the occupancy and effectiveness of therapeutic antibodies. If a therapeutic antibody is occupying the CD79b binding site, a lower concentration of free target may be detectable, which can be an indicator of target engagement and drug activity. Conversely, the presence of high levels of free CD79b could suggest inadequate drug exposure or a biological process that is not being effectively blocked.
| Biological Background | Details |
| Physiological Function of CD79b Molecule | CD79b forms a heterodimer complex with CD79a to construct the core signal transduction unit of B cell receptors on the surface of all mature B lymphocytes. This transmembrane protein mediates intracellular signal cascades after antigen binding, supporting B cell maturation, proliferation, antibody secretion and immune memory formation. Under healthy physiological conditions, CD79b expression is strictly restricted to the B cell lineage without widespread distribution across other somatic cell groups, making it a highly specific biomarker for identifying B cell-derived cell populations. |
| Pathological Alterations in B Cell Malignancies | Malignant transformation of B lymphocytes disrupts normal CD79b regulatory pathways. Tumorous B cells maintain sustained high surface expression of CD79b, while cellular breakdown during disease progression releases soluble free CD79b into peripheral blood circulation. Abundant circulating free CD79b acts as a disease marker reflecting tumor burden and cell turnover status. Hematological disorders tightly linked to dysregulated CD79b signaling include diffuse large B-cell lymphoma and follicular lymphoma, aggressive lymphatic proliferative conditions that rely on aberrant B cell survival signaling for sustained progression. |
| Mechanism of Polatuzumab Vedotin Targeted Therapy | Polatuzumab vedotin belongs to the antibody-drug conjugate class, engineered to selectively bind CD79b molecules on malignant B cell surfaces. After target binding, the entire conjugate complex undergoes cellular internalization, followed by intracellular cleavage to release cytotoxic payloads that disrupt tumor cell division and induce apoptotic death. The design delivers cytotoxic activity specifically to CD79b-positive malignant cells while sparing most healthy non-B cell tissues, greatly reducing systemic toxic side effects compared with traditional chemotherapeutic interventions. |
To navigate the complexities of the immune response and drug-target interactions, researchers rely on sensitive and specific analytical methods. The Enzyme-Linked Immunosorbent Assay (ELISA) is one of the most widely used and robust techniques for quantifying proteins and antibodies in biological samples. ELISA kits are designed to be user-friendly, offer high specificity, and provide reliable data for a wide range of applications, from basic research to clinical trial support. The two kits presented in the following table each serve a distinct purpose in studying immune responses and biomarker detection. They are valuable tools for investigating the presence of antibodies generated against therapeutic or diagnostic peptides, as well as for directly measuring the concentration of specific target molecules in samples.
| Product Name | Analyte Target | Sample Types | Primary Application in Research |
| Anti-Pramlintide ELISA Kit | Anti-Pramlintide Antibodies | Serum, Plasma | Detecting and quantifying a patient's immune response (ADA) to Pramlintide therapy. |
| Pramlintide ELISA Kit | Pramlintide | Serum, Plasma (EDTA, Heparin) | Quantifying the concentration of the free peptide drug Pramlintide in circulation. |
The ability to accurately quantify the immune response and the levels of specific biomarkers is a cornerstone of modern translational science. The development of anti-drug antibodies can significantly impact the safety and efficacy of biologic therapies, while the measurement of free target proteins is essential for confirming target engagement and understanding disease biology. Analytical tools, such as those built on the ELISA platform, empower researchers to dissect these complex interactions with precision. Whether it is detecting an immune response to a therapeutic peptide like Pramlintide, or measuring the concentration of the drug itself, having access to reliable, well-characterized kits is indispensable. By employing these tools, the scientific and medical communities can continue to improve our understanding of immune dynamics, optimize treatment regimens, and ultimately advance the goal of personalized, effective patient care.
| Cat. No. | Product Name | Size | Species Reactivity | Application | Detection Method | |
| DEIA-JY25245 | Anti-Polatuzumab ELISA Kit | 96T | Human | Quantitative | sELISA | Inquiry |
| DEIA-JY25270 | Free Anti-CD79b (Polatuzumab) ELISA Kit | 96T | Human | Quantitative | sELISA | Inquiry |
| Target | Cat. No. | Product Name | Host | Isotype | Application | |
| CD79b | DMAB-CLS25233 | Humanized Anti-Human CD79b-MMAE ADC [Polatuzumab vedotin-piiq] | Human | IgG | Reference Antibody | Inquiry |
| CD79B | CABT-CS560 | Human Anti--human CD79b (Polatuzumab) Monoclonal antibody, clone Polatuzumab | Human | IgG4 | ELISA | Inquiry |
Loading ......
